Transporting medicines by air freight

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides essential guidance on Good Distribution Practice (GDP) specifically tailored for air freight operations. This framework ensures that medicinal products maintain their quality, integrity, and security throughout the complex aviation supply chain. While this guidance does not target a specific company or individual inspection date, it establishes the mandatory standards for all wholesale distributors and logistics providers involved in air transport. The primary issues addressed involve the risk of temperature excursions during ground handling and tarmac transit, lack of visibility in multi-leg journeys, and inadequate security during storage at airport facilities. The regulatory framework is rooted in the Human Medicines Regulations 2012 and EU GDP guidelines, emphasizing the need for robust Quality Management Systems. Key required actions include performing thorough risk assessments of flight routes, validating specialized thermal packaging, and establishing formal technical agreements with airline carriers and freight forwarders. Companies must ensure that sensitive temperature labels are strictly adhered to and that staff at all touchpoints are adequately trained. Furthermore, continuous monitoring of environmental conditions is necessary to prevent product degradation. Compliance with these protocols is vital for maintaining the safety of the medicine supply chain and ensuring that patients receive effective, uncompromised products.